Pegfilgrastim Systematic (IUPAC) name N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene) Clinical data Trade names Neulasta AHFS/Drugs.com MedlinePlus Pregnancy cat. ? Legal status ? Pharmacokinetic data Half-life 15-80 hrs Identifiers CAS number ATC code L03 DrugBank UNII KEGG ChEMBL Chemical data Formula C845H1343N223O243S9 + PEG Mol. mass 39000 g/mol (what is this?)
Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog, filgrastim. Like GCSF, the pegylated form serves to stimulate the level of white blood cells (neutrophils).
Amgen manufactures pegfilgrastim under the brand name Neulasta, and Roche under the name Neulastim. The drug is prepared by coupling a 20 kDa Polyethylene glycol (PEG) molecule to the N-terminus of the filgrastim protein. Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).
Pegfilgrastim treatment can be used to stimulate the bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy. Pegfilgrastim can be given on the first day of chemotherapy. As it supports white blood cell production, using this medicine prophylactically can allow an increased dose intensity of chemotherapy agents. Chemotherapy cycles can be repeated with greater frequency (increased dose-density), diminishing tumor regrowth.
- Neulasta official site
Immunomodulators: Immunostimulants (L03) EndogenousOther protein/peptideOther Exogenous
- ^ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136-137.
- ^ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, p. 139, 158.
- ^ Polovich, M., Whitford, J.M., & Olsen, M. [Eds](2010). Chemotherapy and biotherapy guidelines and recommendations for practice (3rd. ed.). Pittsburgh, PA: Oncology Nursing Society.
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.